You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 9,670,163


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,670,163
Title:Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide
Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
Inventor(s): Hurter; Patricia (Harvard, MA), Rowe; William (Medford, MA), Young; Christopher R. (Waltham, MA), Costache; Adriana (Cambridge, MA), Connelly; Patrick R. (Harvard, MA), Krawiec; Mariusz (Marlborough, MA), Gong; Yuchuan (Waukegan, IL), Feng; Yushi (Zionsville, IN), Trudeau; Martin (Shannon, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:14/852,892
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 9,670,163

Introduction

United States Patent 9,670,163, titled "Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-," is a patent that covers specific solid state forms of a chemical compound. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

The patent, issued on June 6, 2017, pertains to solid state forms, including crystalline and amorphous forms, of a particular chemical compound. This compound is identified as N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-.

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. Here are some key aspects:

  • Claim 1: This claim specifies the solid state forms of the compound, including crystalline and amorphous forms. It details the chemical structure and the physical characteristics of these forms[4].
  • Claim 2: This claim covers methods for preparing the solid state forms, including processes such as crystallization and lyophilization[4].

Dependent Claims

Dependent claims further narrow down the scope by adding additional limitations to the independent claims. For example:

  • Claim 3: This claim specifies particular crystalline forms of the compound, including their X-ray powder diffraction patterns[4].
  • Claim 4: This claim covers the use of these solid state forms in pharmaceutical compositions[4].

Scope of the Patent

The scope of the patent is defined by the claims and the detailed description provided in the patent document.

Chemical Structure

The patent focuses on a specific chemical compound, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-, and its various solid state forms. This includes both crystalline and amorphous forms, each with distinct physical and chemical properties[4].

Pharmaceutical Applications

The solid state forms covered by this patent are intended for use in pharmaceutical compositions. The patent suggests that these forms may have improved stability, solubility, or bioavailability, which are critical factors in drug development[4].

Patent Landscape

Prior Art

The patent cites several prior art documents, including U.S. Pat. Nos. 8,324,242, 8,354,427, and others, which relate to similar compounds or methods of preparation. This indicates that the patent builds upon existing knowledge in the field but introduces novel aspects related to the specific solid state forms of the compound[5].

Related Patents

The patent is part of a larger family of patents related to pharmaceutical compounds and their solid state forms. For instance, patents like U.S. Pat. Nos. 7,495,103 and 7,645,789 cover related compounds and methods, highlighting the complex and interconnected nature of pharmaceutical patent landscapes[5].

Claim Coverage and Patent Analytics

To fully understand the value and coverage of this patent, patent analytics tools can be employed.

Claim Coverage Matrix

A Claim Coverage Matrix, as described by patent analytics services, can help identify which claims of the patent actively protect the intellectual property and where gaps or opportunities exist. This involves categorizing patents by claims and overarching scope concepts, which can link claims on similar patents[3].

Scope Concepts

The scope concepts of the patent claims can be categorized into high, medium, or low value based on their current and potential future relevance to the company. For example, claims related to the crystalline forms of the compound might be considered high value if they are currently used in a marketed drug, while claims related to less common forms might be medium or low value[3].

Practical Applications and Future Directions

Pharmaceutical Development

The solid state forms covered by this patent can be crucial in pharmaceutical development, particularly in enhancing the stability, solubility, or bioavailability of the drug. This can lead to improved efficacy and safety profiles for patients.

Design Opportunities

Interactive claim charts generated by patent analytics software can help engineers, scientists, and management identify new design options and future directions. For instance, if a particular scope concept is applicable to a target product or method, it can highlight areas for innovation and development[3].

Key Takeaways

  • Specific Solid State Forms: The patent covers specific crystalline and amorphous forms of the compound N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-.
  • Pharmaceutical Applications: These forms are intended for use in pharmaceutical compositions, potentially improving drug stability, solubility, or bioavailability.
  • Patent Landscape: The patent is part of a broader landscape of related patents covering similar compounds and methods.
  • Patent Analytics: Tools like Claim Coverage Matrix and scope concepts can help in understanding the value and coverage of the patent.

FAQs

Q: What is the main subject of United States Patent 9,670,163? A: The main subject is the solid state forms, including crystalline and amorphous forms, of the chemical compound N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-.

Q: What are the key claims of this patent? A: The key claims include the specification of the solid state forms, methods for preparing these forms, and their use in pharmaceutical compositions.

Q: How does this patent fit into the broader patent landscape? A: It is part of a larger family of patents related to pharmaceutical compounds and their solid state forms, citing several prior art documents.

Q: What is the practical application of this patent? A: The patent can enhance the stability, solubility, or bioavailability of the drug, leading to improved efficacy and safety profiles.

Q: How can patent analytics tools help in understanding this patent? A: Tools like Claim Coverage Matrix and scope concepts can help identify which claims actively protect the intellectual property and highlight areas for future innovation.

Sources

  1. US9670163B2 - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-. Google Patents.
  2. US20230210995A1 - Localized expression of ... - Google Patents. Google Patents.
  3. Patent Analytics | Intellectual Property Law. SLWIP.
  4. US9670163B2 - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-. Google Patents.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,670,163

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms Inc KALYDECO ivacaftor GRANULE;ORAL 207925-004 May 3, 2023 RX Yes No 9,670,163 ⤷  Subscribe Y TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO ⤷  Subscribe
Vertex Pharms Inc KALYDECO ivacaftor GRANULE;ORAL 207925-005 May 3, 2023 RX Yes No 9,670,163 ⤷  Subscribe Y TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO ⤷  Subscribe
Vertex Pharms Inc KALYDECO ivacaftor GRANULE;ORAL 207925-003 Apr 29, 2019 RX Yes No 9,670,163 ⤷  Subscribe Y METHOD OF TREATING CYSTIC FIBROSIS ⤷  Subscribe
Vertex Pharms Inc KALYDECO ivacaftor GRANULE;ORAL 207925-003 Apr 29, 2019 RX Yes No 9,670,163 ⤷  Subscribe Y TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO ⤷  Subscribe
Vertex Pharms Inc KALYDECO ivacaftor GRANULE;ORAL 207925-001 Mar 17, 2015 RX Yes No 9,670,163 ⤷  Subscribe Y METHOD OF TREATING CYSTIC FIBROSIS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.